Treatment of Vaccinia and Cowpox Virus Infections in Mice with CMX001 and ST-246
AbstractAlthough a large number of compounds have been identified with antiviral activity against orthopoxviruses in tissue culture systems, it is highly preferred that these compounds have activity in vivo before they can be seriously considered for further development. One of the most commonly used animal models for the confirmation of this activity has been the use of mice infected with either vaccinia or cowpox viruses. These model systems have the advantage that they are relatively inexpensive, readily available and do not require any special containment facilities; therefore, relatively large numbers of compounds can be evaluated in vivo for their activity. The two antiviral agents that have progressed from preclinical studies to human safety trials for the treatment of orthopoxvirus infections are the cidofovir analog, CMX001, and an inhibitor of extracellular virus formation, ST-246. These compounds are the ones most likely to be used in the event of a bioterror attack. The purpose of this communication is to review the advantages and disadvantages of using mice infected with vaccinia and cowpox virus as surrogate models for human orthopoxvirus infections and to summarize the activity of CMX001 and ST-246 in these model infections.
Share & Cite This Article
Quenelle, D.C.; Kern, E.R. Treatment of Vaccinia and Cowpox Virus Infections in Mice with CMX001 and ST-246. Viruses 2010, 2, 2681-2695.
Quenelle DC, Kern ER. Treatment of Vaccinia and Cowpox Virus Infections in Mice with CMX001 and ST-246. Viruses. 2010; 2(12):2681-2695.Chicago/Turabian Style
Quenelle, Debra C.; Kern, Earl R. 2010. "Treatment of Vaccinia and Cowpox Virus Infections in Mice with CMX001 and ST-246." Viruses 2, no. 12: 2681-2695.